Both sets of holders post nonsense including you. I'll clear up two of your misconceptions:
1. The spodumene market is opaque to start with, and quality matters and hence why difficult to guage prices.
2. Sulphate is a step towards carbonate/hydroxide, and you produce that before producing the others. You might need to understand a process flowsheet to get that, but if interested refer to my first post yesterday on LTR (who are also assessing an option of selling either sulphate or hydroxide). Yes you produce sulphate before you produce the other chemicals , accept most others simply move along the process flowsheet to either produce carbonate or hydroxide, rather than stop there and sell sulphate. Why is sulphate been considered now - it is called options, why some batteries require a lithium carbonate input (like solid state batteries) whilst others require a hydroxide input (read NCA/NCM batteries). It is either based on broadening end market customers pot etial whilst getting higher value for the product sold and also used to reuce transport costs, if required. I'll leave it at that, but because sulphate production requires 3 - 4 tonnes of 6% grade spodumene to produce, whilst lithium hydroxide monohydrate takes 6.5 tonnes to produce, pricing it is not as difficult as you imply is my point. Called contract negotiations.
Have a nice day.
All IMO
- Forums
- ASX - By Stock
- FFX
- Ann: GOULAMINA LITHIUM PROJECT DEFINITIVE FEASIBILITY STUDY
Ann: GOULAMINA LITHIUM PROJECT DEFINITIVE FEASIBILITY STUDY, page-94
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online